Repositioning HIV protease inhibitors as cancer therapeutics

Current Opinion in HIV and AIDS

Volumn 3, Issue 6, 2008, Pages 666-675

  Bernstein, Wendy B ^a,b   Dennis, Phillip A ^a  

^a NATIONAL NAVAL MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Akt; Apoptosis; Autophagy; Endoplasmic reticulum stress; Protease inhibitors

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CISPLATIN; GEMCITABINE; GROWTH FACTOR RECEPTOR; IMATINIB; INDINAVIR; LOPINAVIR; MAMMALIAN TARGET OF RAPAMYCIN; MEVINOLIN; NELFINAVIR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INSULIN RESISTANCE; LIPODYSTROPHY; LIPOSARCOMA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEINASE INHIBITION; RADIATION DOSE; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 67649580245     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328313915d     Document Type: Review

References (65)

1. Karacostas V, Nagashima K, Gonda MA, Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A 1989; 86:8964-8967.
2. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science (New York, NY) 1990; 248:358-361.
3. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995; 92:2484-2488.
4. Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999; 274:35734-35740.
5. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998; 102:79-87.
6. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998; 351:723-724.
7. Levitz SM. Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med 1998; 338:1074-1075.
8. Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-953.
9. Lecossier D, Bouchonnet F, Schneider P, et al. Discordant increases in CD4+ T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001; 183:1009-1016.
10. Piketty C, Weiss L, Thomas F, et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis 2001; 183:1328-1335.
11. Niehues T, HorneffG, Megahed M, et al. Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy. AIDS (London, England) 1999; 13:1148-1149.
12. Monini P, Sgadari C, Toschi E, et al. Antitumour effects of antiretroviral therapy. Nat Rev 2004; 4:861-875.
13. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002; 99:3771-3779.
14. Gaedicke S, Firat-Geier E, Constantiniu O, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62:6901-6908.
15. Ikezoe T, Saito T, Bandobashi K, et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 2004; 3:473-479.
16. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64:7426-7431.
17. Yang Y, Ikezoe T, Takeuchi T, et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005; 96:425-433.
18. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (London, England) 1998; 12:F51-F58.
19. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS (London, England) 1998; 12:F167-F173.
20. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84:1932-1937.
21. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diab Metab 1999; 25:225-232.
22. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
23. Gagnon A, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998; 352:1032.
24. Zhang B, MacNaul K, Szalkowski D, et al. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999; 84:4274-4277.
25. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275:41325-41332.
26. Nguyen AT, Gagnon A, Angel JB, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS (London, England) 2000; 14:2467-2473.
27. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
28. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
29. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996; 413:2-28.
30. Schutt M, Zhou J, Meier M, Klein HH. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. J Endocrinol 2004; 183:445-454.
31. Ben-Romano R, Rudich A, Tirosh A, et al. Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta. Diabetologia 2004; 47:1107-1117.
32. Ben-Romano R, Rudich A, Torok D, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS (London, England) 2003; 17:23-32.
33. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-20254.
34. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (New York, NY) 2001; 292:1728-1731.
35. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24:7455-7464.
36. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in nonsmall-cell lung cancer tumors. J Clin Oncol 2006; 24:306-314.
37. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22:4217-4226.
38. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/ Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11:32-50. An overview of the Akt pathway, mechanisms of activation in malignancy and the use of various agents either alone or in combination to inhibit the pathway.
39. Gupta V, Samuleson CG, Su S, Chen TC. Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus 2007; 23:E9.
40. Yang Y, Ikezoe T, Nishioka C, et al. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. Br J Cancer 2006; 95:1653-1662.
41. Gupta AK, Cerniglia GJ, Mick R, et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65:8256-8265.
42. Cuneo KC, Tu T, Geng L, et al. HIV protease inhibitors enhance the efficacy of irradiation. Cancer Res 2007; 67:4886-4893. Instead focusing on the cancer cell, these investigators focus on the ability of protease inhibitor to sensitize human vascular endothelial cells to radiation. The effect was associated with inhibition of Akt phosphorylation. Ionizing radiation and nelfinavir had more than an additive effect in vivo.
43. Jiang Z, Pore N, Cerniglia GJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2007; 67:4467-4473.
44. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxiainducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006; 66:9252-9259.
45. Srirangam A, Mitra R, Wang M, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res 2006; 12:1883-1889.
46. Gupta AK, Li B, Cerniglia GJ, et al. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (New York, NY) 2007; 9:271-278. Expanding on early work, investigators propose the unfolded protein response following protease inhibition as the means by which inhibition of Akt reverses radiation resistance.
47. Chow WA, Guo S, Valdes-Albini F. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. Anticancer Drugs 2006; 17:891-903.
48. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13:5183-5194. Investigators showed that nelfinavir was consistently the most potent of the six protease inhibitors tested in terms of growth inhibition. Caspase-dependent apoptosis, endoplasmic reticulum stress, and autophagy were all proposed as mechanisms of action of the protease inhibitors. Akt activation was not consistently observed.
49. Jiang W, Mikochik PJ, Ra JH, et al. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 2007; 67:1221-1227. Investigators tested melanoma cell lines against nelfinavir. They proposed that the cell cycle arrest was due to enhanced proteasome-mediated degradation of cdk25A.
50. Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007; 67:10920-10928. Investigators showed that the growth inhibition of nelfinavir and atazanavir in glioma cell lines was due to proteasome inhibition resulting in an accumulation of unfolded proteins and activation of the unfolded protein response.
51. Pajonk F, Himmelsbach J, Riess K, et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62:5230-5235.
52. Issat T, Nowis D, Jakobisiak M, Golab J. Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncol Rep 2004; 12:1371-1375.
53. Piccinini M, Rinaudo MT, Anselmino A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther 2005; 10:215-223.
54. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11:813-825.
55. Grana TM, Rusyn EV, Zhou H, et al. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. Cancer Res 2002; 62:4142-4150.
56. Gupta AK, Bakanauskas VJ, Cerniglia GJ, et al. The Ras radiation resistance pathway. Cancer Res 2001; 61:4278-4282.
57. Gupta AK, Cerniglia GJ,Mick R, et al. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003; 56:846-853.
58. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-337.
59. Gills JJ, Lopiccolo J, Dennis PA. Nelfinavir, a new anticancer drug with pleiotropic effects and many paths to autophagy. Autophagy 2008; 4:107-109. This paper is a follow-up report looking more closely at the effects of nelfinavir on autophagy. The authors raise the concern that despite the presence of other markers of autophagy, beclin-1 was not expressed.
60. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 2006; 13:363-373.
61. WuJ, Kaufman RJ. From acute ER stress to physiological roles of the unfolded protein response. Cell Death Differ 2006; 13:374-384.
62. Parker RA, Flint OP, Mulvey R, et al. Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005; 67:1909-1919.
63. Cuervo AM. Autophagy: many paths to the same end. Mol Cell Biochem 2004; 263:55-72.
64. Kelekar A. Autophagy. Ann N Y Acad Sci 2005; 1066:259-271.
65. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008; 26:2699-2706. Investigators report data from the first ever clinical trial testing nelfinavir as a radiation sensitizer in locally advanced pancreatic cancer. They found no significant toxicity attributable to nelfinavir and observed a response rate of 50% to chemoradiation therapy. Responses did not correlate with Akt activation status.